Physician profile
Mark Robert Goldblatt
NPI 1821087537
$2,752.89
in general payments reported to CMS, 2019-2025
17 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.87 · 2020: $16.24 · 2021: $201 · 2022: $2,012 · 2023: $168 · 2024: $33.25 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,415.92 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.30 | 2021-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $153.43 | 2022 | |
| Electromed, INC. | $134.89 | 2022-2024 | Smartvest |
| Pulmonx Corporation | $117.79 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $96.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $89.94 | 2022 | |
| Grifols USA, LLC | $74.74 | 2022-2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $41.68 | 2022 | |
| Philips North America LLC | $34.86 | 2022 | |
| Genzyme Corporation | $28.24 | 2022 | |
| Olympus America INC. | $26.10 | 2021-2022 | |
| Mylan Specialty L.P. | $18.88 | 2022 | |
| Pfizer INC. | $18.73 | 2022 | |
| Baxter Healthcare | $16.51 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $16.24 | 2020 | |
| Ambu INC. | $14.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goldblatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.